Taxane‐based versus platinum‐based chemotherapy in early recurrent gastric cancer after radical surgery with S‐1 adjuvant chemotherapy: A multi‐institutional retrospective analysis

2021 ◽  
Author(s):  
Sakae Nagaoka ◽  
Hiroharu Yamashita ◽  
Yasuyuki Seto ◽  
Muneharu Fujisaki ◽  
Norio Mitsumori ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Retrospective Analysis ◽  
Radical Surgery ◽  
Recurrent Gastric Cancer ◽  
Platinum Based Chemotherapy

EFFICIENCY OF ADJUVANT XELOX CHEMOTHERAPY FOR PATIENTS WITH RESECTABLE GASTRIC IN RUSSIA (SINGLE INSTITUTION RETROSPECTIVE STUDY)

2019 ◽  
Vol 65 (2) ◽  
pp. 256-262
Author(s):  
Ivan Stilidi ◽  
Sergey Nered ◽  
Aleksey Kalinin ◽  
Olesya Rossomakhina ◽  
Anton Barchuk
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Surgery ◽  
Univariate Analysis ◽  
European Population ◽  
Single Institution ◽  
Regional Lymph Nodes ◽  
Lymph Nodes Metastasis ◽  
Retrospective Assessment ◽  
Resectable Gastric Cancer

Introduction. The effectiveness of the Asian regimen of adjuvant chemotherapy in patients with gastric cancer in the European population remains unclear. The aim of our study was a retrospective assessment of adjuvant chemotherapy (XELOX regimen) after radical surgery (R0) on overall survival. Methods. Database of pts with resectable gastric cancer with stage >pT3 and/or pN+ and M0, who were operated (R0) at single oncological institution during 2007-2017 was reviewed. In univariate and multivariate analyzes were included demographic characteristics, type of tumor according to Lauren, stage, type of treatment and others. Results. 396 pts were identified and 286 were available for analysis.106 (37%) pts received at least one cycle of adjuvant chemotherapy. In univariate analysis, 5OS rate was 64% [95% Cl, 52-80] и 56% [95% Cl, 48-64; p=0,21] in patients received adjuvant chemotherapy and only surgical treatment. After stratifying patients depending on the regional lymph nodes metastasis, 5OS rate in pts with pN1-3 was 69% [95% CI, 57-85] vs 47% [95% CI, 39-58; p = 0,01], respectively...

scholarly journals Retrospective analysis of the cases died of the recurrent gastric cancer.

1987 ◽  
Vol 20 (9) ◽  
pp. 2097-2102 ◽  
Author(s):  
Hiroshi ISOZAKI ◽  
Kunio OKAJIMA ◽  
Akira FUJIWARA ◽  
Masayuki YASUDA ◽  
Yasuo KAWASHIMA ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Retrospective Analysis ◽  
Recurrent Gastric Cancer

scholarly journals Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis

2011 ◽  
Vol 15 (3) ◽  
pp. 245-251 ◽  
Author(s):  
Kohei Shitara ◽  
Satoshi Morita ◽  
Kazumasa Fujitani ◽  
Shigenori Kadowaki ◽  
Nobuhiro Takiguchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Retrospective Analysis ◽  
Combination Chemotherapy

Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15615-e15615
Author(s):  
U. Toh ◽  
H. Yamana ◽  
K. Koufuji ◽  
T. Mine ◽  
K. Aoyagi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Single Agent ◽  
First Line ◽  
Curative Gastrectomy ◽  
Intention To Treat ◽  
Recurrent Gastric Cancer ◽  
Grade 3 ◽  
Treat Analysis

e15615 Background: Taxanes and S-1 have been shown to be effective in patients with advanced gastric cancer and they have a considerable single-agent activity, respectively. We evaluated the combination of paclitaxel and S-1 as first-line chemotherapy for advanced or recurrent gastric cancer (AGC). Methods: All patients with histologically confirmed AGC with unresectable or metastatic diseases, measurable lesions, PS 0–2, age between 18 and 75, and no contraindication to chemotherapy were eligible in this study. Prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. Treatment included S-1 80 mg/m2 p.o. twice daily on days 1–14 and paclitaxel 60 mg/m2 i.v. on day 1, 8, 15 with a 2-week interval until disease progression or unacceptable toxicities. Results: Between MAY 2004 and Match 2008, total 20 pts were enrolled in this study. The median age was 56.5 years (range, 38–73). Nine pts had recurrent disease after previous curative gastrectomy and 8 had previous adjuvant chemotherapy. After a median 4 (range, 1–9) cycles of chemotherapy, 12 pts were evaluable for toxicity and 20 pts for response. In intention-to-treat analysis, the overall response rate was 62.9% (95% C.I., 36.2–69.6%), including 0 CR, 6 PRs, 8 SDs, and 6 PDs. After a median follow-up of 8.6 months (range, 0.9–17.9), median time to progression was 6.3 months (95% C.I., 3.6–6.9) and median overall survival was 11.6 months (95% C.I., 8.5–20.7). Commonly observed grade 3/4 adverse events were neutropenia (40% of patients), anemia (10%). There was no neutropenic fever or treatment-related death. Conclusions: The combination of paclitaxel and S-1 appear to have well efficacy, manageable toxicity and is well tolerated in patients with AGC. Further studies of this combination should be considered. No significant financial relationships to disclose.

Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: A retrospective analysis.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e14563-e14563
Author(s):  
K. Tanabe ◽  
T. Suzuki ◽  
N. Tokumoto ◽  
H. Yamamoto ◽  
K. Yoshida ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Combination Therapy ◽  
Retrospective Analysis ◽  
Line Treatment ◽  
First Line ◽  
Recurrent Gastric Cancer ◽  
First Line Treatment

scholarly journals Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Yonghe Chen ◽  
Dan Liu ◽  
Jian Xiao ◽  
Jun Xiang ◽  
Aihong Liu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Gastric Cancer ◽  
Cox Regression ◽  
Radical Surgery ◽  
Survival Rates ◽  
Receiver Operating Curve ◽  
R0 Resection ◽  
Clinical Parameters

Background. Neoadjuvant chemotherapy (NAC) with subsequent radical surgery has become a popular treatment modality for advanced gastric cancer (AGC) worldwide. However, the survival benefit is still controversial, and prognostic factors remain undetermined. Aim. To identify clinical parameters that are associated with the survival of AGC patients after NAC and radical surgery and to establish a nomogram integrating multiple factors to predict survival. Methods. We reviewed the medical profiles of 215 AGC patients who received NAC and radical resection, and clinical parameters concerning NAC, surgery, pathological findings, and adjuvant chemotherapy were analyzed using a Cox regression model to determine their impact on survival. Based on these factors, a nomogram was developed and validated. Results. The overall 1-year and 3-year survival rates were 85.8% and 55.6%, respectively. Younger age (<60 years old), increased examined lymph nodes (exLNs), successful R0 resection, the achievement of pathological complete response (pCR), and acceptance of adjuvant chemotherapy were positive predictors of survival. The C-index of the established nomogram was 0.785. The area under receiver operating curve (ROC) at 1/3 years of prediction was 0.694/0.736, respectively. The model showed an ideal calibration following internal bootstrap validation. Conclusion. A nomogram predicting survival after NAC and surgery was established. Since this nomogram exhibited satisfactory and stable predictive power, it can be inferred that this is a practical tool for predicting AGC patient survival after NAC and radical surgery.

Prognostic value of subclassification of pT2 stage in patients with gastric cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16070-e16070
Author(s):  
Kang He ◽  
Xiaohua Wang ◽  
Cheng Chen ◽  
Yingying Jiang ◽  
Yue Shi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Tumor Invasion ◽  
Radical Surgery ◽  
Muscularis Propria ◽  
Staging System ◽  
Tnm Staging ◽  
Tnm Staging System ◽  
Pn Stage ◽  
Better Than

e16070 Background: The data about prognosis difference of patients with pT2 stage gastric cancer (GC) after radical surgery is diverse. The latest TNM staging system does not define details for the pT2 stage subclassification. The purpose of this study is to investigate the survival difference according to depth of tumor muscularis propria involvement and find biomarker to reinforce the prognostic and therapy-guided ability of TNM staging system. Methods: A total of 380 patients with pT2 GC after radical surgery were retrospectively analyzed, including 185 in sMP (superficial muscularis propria) group and 195 in dMP (deep muscularis propria) group. The log-rank test was used to identify survival outcomes. Independent factors were identified by multivariable Cox proportional hazard model for OS. Results: The overall survival (OS) of patients in sMP group was significantly better than patients in dMP group (P = 0.007). On multivariate analysis, age (＜60 vs ≥60: P = 0.004, HR, 2.075(95%CI: 1.261-3.414)), primary location (P = 0.002, U vs M: 0.985(0.509-1.909); U vs L: 0.400(0.235-0.680)), depth of tumor invasion (sMP vs dMP: P = 0.050, 1.584(1.261-3.414), pN stage (P = 0.000, N0 vs N1: 2.304(1.364-3.890); N0 vs N2: 1.879(0.967-3.652); N0 vs N3: 5.335(2.533-11.237)), expression of p53 (negative vs positive: P = 0.016, 1.793(1.117-2.879)) were independent prognostic factors for the OS. In pN0 stage tumor, the sMP group had a significantly better OS than the dMP group (P = 0.014). When classified as N+, there was no obviously difference of OS between two groups (P = 0.384). When patients were stratified according to the depth of tumor invasion and pN stage, the OS was not significant difference between dMPN0 group and sMPN1-2 group (P = 0.100), the OS of patients with adjuvant chemotherapy were statistically better than those without in dMPN0 group (P = 0.045), but not significance in sMPN1-2 group (P = 0.486). After further grouping according to adjuvant chemotherapy status, in comparison to sMPN1-2 patients, dMPN0 patients with adjuvant chemotherapy had better OS (P = 0.015), but not significance in patients without (P = 0.599). Upon stratification according to the expression of p53, in p53-positive group, greater OS could be observed in patients with sMPN0 than patients with dMPN0 (P = 0.002). Similar OS could be seen between dMPN0 patients with p53-positive and T2N1-2 patients (P = 0.872). Conclusions: For pT2 gastric cancer patients, there were differences in survival outcomes for sMP and dMP invasion. The prognosis of dMPN0 patients were similar to patients with sMPN1-2, and dMPN0 patients who accepted adjuvant chemotherapy had an improved prognosis than those without. Appropriate adjuvant chemotherapy should be considered for patients with dMPN0 stage. In addition, positive expression of p53 could be potential factors to identify the different prognoses for patients with pT2 gastric cancers.

Sign in / Sign up

Export Citation Format

Share Document